Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Tandem Diabetes Care's operating assets for the quarter that ended in Jun. 2026 was R$3,614 Mil. Tandem Diabetes Care's operating liabilities for the quarter that ended in Jun. 2026 was R$1,473 Mil. Tandem Diabetes Care's Total Assets for the quarter that ended in Mar. 2026 was R$6,023 Mil. Therefore, Tandem Diabetes Care's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2026 was 0.36.
Tandem Diabetes Care Scaled Net Operating Assets Related Terms
Tandem Diabetes Care Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care Scaled Net Operating Assets Chart
BSP:T2ND34 vs CNMD, ATEC, ENOV: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, Tandem Diabetes Care's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.36 mean?
Tandem Diabetes Care (BSP:T2ND34) has a Scaled Net Operating Assets of 0.36 as of Jun. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Scaled Net Operating Assets too high?
Tandem Diabetes Care's current Scaled Net Operating Assets is 0.36. Overall, Tandem Diabetes Care has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Scaled Net Operating Assets compare to CNMD and ATEC?
Tandem Diabetes Care's Scaled Net Operating Assets of 0.36 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Scaled Net Operating Assets is 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (BSP:T2ND34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.36, compared to a current price of R$5.98 — trading 28.5% below its estimated fair value. The current Scaled Net Operating Assets is 0.36. Tandem Diabetes Care's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Tandem Diabetes Care (BSP:T2ND34), the current Scaled Net Operating Assets is 0.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (BSP:T2ND34) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of R$5.98 is trading 28.5% below its estimated GF Value™ of R$8.36.
GuruFocus considers Tandem Diabetes Care to be Modestly Undervalued.
Key valuation signals for BSP:T2ND34:
Scaled Net Operating Assets: 0.36
GF Value™: R$8.36 vs. price of R$5.98 (28.5% below fair value)
No single metric tells the full story. See the BSP:T2ND34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes Care Inc. is a medical device company that designs, develops, and commercializes insulin delivery systems for people with diabetes. Its flagship product is the t:slim X2 insulin pump, which integrates with continuous glucose monitoring systems and automated insulin dosing software, including its Control-IQ technology. The company also offers the smaller Mobi pump and has been developing the Sigi tubeless patch pump. Tandem sells durable pumps and recurring consumables such as infusion sets and cartridges, generating a significant portion of revenue from repeat purchases. Its primary market is the United States, which accounts for the majority of sales, with additional revenue from other developed countries. Customers include individuals with type 1 and type 2 diabetes, healthcare providers, and diabetes clinics. The company operates through direct sales and distributors, deriving revenue from both hardware and disposable supplies.
49GF Score
Get the complete analysis for BSP:T2ND34
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:T2ND34 has been successfully added to your 
